Patents by Inventor John MARLETT

John MARLETT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
    Patent number: 10864217
    Abstract: Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV).
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: December 15, 2020
    Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Lars Pache, Sumit K. Chanda, Mitchell Dennis Vamos, Nicholas David Peter Cosford, Peter Teriete, John Marlett, Arturo Diaz, John A. T. Young
  • Use of Inhibitor of Apoptosis Protein (IAP) Antagonists in HIV Therapy
    Publication number: 20200121693
    Abstract: Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV).
    Type: Application
    Filed: May 24, 2019
    Publication date: April 23, 2020
    Inventors: Lars PACHE, Sumit K. CHANDA, Mitchell Dennis VAMOS, Nicholas David Peter COSFORD, Peter TERIETE, John MARLETT, Arturo DIAZ, John A.T. YOUNG
  • Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
    Patent number: 10300074
    Abstract: Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV). Described herein is the use of IAP antagonists in the treatment of human immunodeficiency virus (HIV) in a mammal, alone or in combination with other therapeutic agents used in HIV therapy. In one aspect, provided herein is a method of treating human immunodeficiency virus (HIV) in an individual in need thereof comprising administering a therapeutically effective amount of at least one inhibitor of apoptosis proteins (IAP) antagonist.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: May 28, 2019
    Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Lars Pache, Sumit K. Chanda, Mitchell Dennis Vamos, Nicholas David Peter Cosford, Peter Teriete, John Marlett, Arturo Diaz, John A. T. Young
  • Use of Inhibitor of Apoptosis Protein (IAP) Antagonists in HIV Therapy
    Publication number: 20170196879
    Abstract: Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (1APs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV). Described herein is the use of IAP antagonists in the treatment of human immunodeficiency virus (HIV) in a mammal, alone or in combination with other therapeutic agents used in HIV therapy. In one aspect, provided herein is a method of treating human immunodeficiency virus (HIV) in an individual in need thereof comprising administering a therapeutically effective amount of at least one inhibitor of apoptosis proteins (IAP) antagonist.
    Type: Application
    Filed: June 4, 2015
    Publication date: July 13, 2017
    Inventors: Lars PACHE, Sumit K. CHANDA, Mitchell Dennis VAMOS, Nicholas David Peter COSFORD, Peter TERIETE, John MARLETT, Arturo DIAZ, John A. T. YOUNG
  • Detection of security marks simulating natural defects for embedding information in documents
    Patent number: 8888010
    Abstract: A system for generating a security mark includes a data reception component that receives information. A security mark generation component in communication with the data reception component generates at least one security mark configuration based at least in part upon the received information. The at least one security mark configuration includes at least one simulation mark which resembles a natural feature. An application component applies one configuration of the at least one security mark configurations to a recipient. The applied security mark configuration obeys at least one rule whereby the security mark is distinguishable from the natural feature which it resembles by a system for detection of security marks.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: November 18, 2014
    Assignee: Xerox Corporation
    Inventors: Zhigang Fan, Reiner Eschbach, Calvin John Marlett, William A. Fuss, James R. Low, Shen-ge Wang
  • DETECTION OF SECURITY MARKS SIMULATING NATURAL DEFECTS FOR EMBEDDING INFORMATION IN DOCUMENTS
    Publication number: 20120024953
    Abstract: A system for generating a security mark includes a data reception component that receives information. A security mark generation component in communication with the data reception component generates at least one security mark configuration based at least in part upon the received information. The at least one security mark configuration includes at least one simulation mark which resembles a natural feature. An application component applies one configuration of the at least one security mark configurations to a recipient. The applied security mark configuration obeys at least one rule whereby the security mark is distinguishable from the natural feature which it resembles by a system for detection of security marks.
    Type: Application
    Filed: September 21, 2011
    Publication date: February 2, 2012
    Applicant: Xerox Corporation
    Inventors: Zhigang Fan, Reiner Eschbach, Calvin John Marlett, William A. Fuss, James R. Low, Shen-ge Wang